Simmi Dube1, Barbara J Norby, Vishwanath Pattan, Rickey E Carter, Ananda Basu, Rita Basu. 1. Endocrine Research Unit (S.D., B.J.N., V.P., A.B., R.B.), Division of Endocrinology, Diabetes, Metabolism, and Nutrition, and Division of Biomedical Statistics and Informatics (R.E.C.), Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905.
Abstract
CONTEXT: The role of 11β-hydroxysteroid dehydrogenase types 1 (11β-HSD-1) and 2 (11β-HSD-2) enzymes in sc adipose tissue is controversial. OBJECTIVE: The objective of the study was to determine the activity of 11β-HSD-1 and -2 enzymes in the abdominal and leg sc adipose tissue in obesity and diabetes. DESIGN: 11β-HSD-1 and -2 enzyme activities in abdominal and leg sc adipose tissue were measured by infusing [2,2,4,6,6,12,12-(2)H7] cortisone (D7 cortisone) and [9,12,12-(2)H3] cortisol (D3 cortisol) via microdialysis catheters placed in sc fat depots. SETTING: The study was conducted at the Mayo Clinic Clinical Research Unit. PARTICIPANTS: Lean nondiabetic (n = 13), overweight/obese nondiabetic (n = 15), and overweight/obese participants with type 2 diabetes mellitus (n = 15) participated in the study. MAIN OUTCOME MEASURES: The conversion of infused D7 cortisone to D7 cortisol (via 11β-HSD reductase activity) and D3 cortisol to D3 cortisone (via 11β-HSD dehydrogenase activity) in sc adipose tissue. RESULTS: Enrichment of D7 cortisone and D3 cortisol were similar in the effluents from both sites in all groups. D3 cortisone enrichment did not differ in the three cohorts, indicating that 11β-HSD-2 enzyme activity (conversion of cortisol to cortisone) occurs equally in all groups. However, D7 cortisol enrichment was detectable in abdominal sc fat of overweight/obese participants with type 2 diabetes mellitus only, implying 11β-HSD-1 reductase activity (conversion of cortisone to cortisol) occurs in obese subjects with type 2 diabetes. CONCLUSIONS: There is conversion of cortisone to cortisol via the 11β-HSD-1 enzyme pathway in abdominal sc fat depots in overweight/obese participants with type 2 diabetes mellitus. This observation has significant implications for developing tissue-specific 11β-HSD-1 inhibitors in type 2 diabetes mellitus.
CONTEXT: The role of 11β-hydroxysteroid dehydrogenase types 1 (11β-HSD-1) and 2 (11β-HSD-2) enzymes in sc adipose tissue is controversial. OBJECTIVE: The objective of the study was to determine the activity of 11β-HSD-1 and -2 enzymes in the abdominal and leg sc adipose tissue in obesity and diabetes. DESIGN: 11β-HSD-1 and -2 enzyme activities in abdominal and leg sc adipose tissue were measured by infusing [2,2,4,6,6,12,12-(2)H7] cortisone (D7 cortisone) and [9,12,12-(2)H3] cortisol (D3 cortisol) via microdialysis catheters placed in sc fat depots. SETTING: The study was conducted at the Mayo Clinic Clinical Research Unit. PARTICIPANTS: Lean nondiabetic (n = 13), overweight/obese nondiabetic (n = 15), and overweight/obeseparticipants with type 2 diabetes mellitus (n = 15) participated in the study. MAIN OUTCOME MEASURES: The conversion of infused D7 cortisone to D7 cortisol (via 11β-HSD reductase activity) and D3 cortisol to D3 cortisone (via 11β-HSD dehydrogenase activity) in sc adipose tissue. RESULTS: Enrichment of D7 cortisone and D3 cortisol were similar in the effluents from both sites in all groups. D3 cortisone enrichment did not differ in the three cohorts, indicating that 11β-HSD-2 enzyme activity (conversion of cortisol to cortisone) occurs equally in all groups. However, D7 cortisol enrichment was detectable in abdominal sc fat of overweight/obeseparticipants with type 2 diabetes mellitus only, implying 11β-HSD-1 reductase activity (conversion of cortisone to cortisol) occurs in obese subjects with type 2 diabetes. CONCLUSIONS: There is conversion of cortisone to cortisol via the 11β-HSD-1 enzyme pathway in abdominal sc fat depots in overweight/obeseparticipants with type 2 diabetes mellitus. This observation has significant implications for developing tissue-specific 11β-HSD-1 inhibitors in type 2 diabetes mellitus.
Authors: J H Goedecke; D J Wake; N S Levitt; E V Lambert; M R Collins; N M Morton; R Andrew; J R Seckl; B R Walker Journal: Clin Endocrinol (Oxf) Date: 2006-07 Impact factor: 3.478
Authors: Jonathan M Hazlehurst; Laura L Gathercole; Maryam Nasiri; Matthew J Armstrong; Sarah Borrows; Jinglei Yu; Anton J M Wagenmakers; Paul M Stewart; Jeremy W Tomlinson Journal: J Clin Endocrinol Metab Date: 2013-02-20 Impact factor: 5.958
Authors: G Valsamakis; A Anwar; J W Tomlinson; C H L Shackleton; P G McTernan; R Chetty; P J Wood; A K Banerjee; G Holder; A H Barnett; P M Stewart; S Kumar Journal: J Clin Endocrinol Metab Date: 2004-09 Impact factor: 5.958
Authors: J Sutinen; K Kannisto; E Korsheninnikova; T Nyman; E Ehrenborg; R Andrew; D J Wake; A Hamsten; B R Walker; H Yki-Järvinen Journal: Diabetologia Date: 2004-09-29 Impact factor: 10.122
Authors: Katherine A Hughes; Konstantinos N Manolopoulos; Javaid Iqbal; Nicholas L Cruden; Roland H Stimson; Rebecca M Reynolds; David E Newby; Ruth Andrew; Fredrik Karpe; Brian R Walker Journal: Diabetes Date: 2012-04-17 Impact factor: 9.461
Authors: Jiachang Gong; Lisa Iacono; Ramaswamy A Iyer; William G Humphreys; Ming Zheng Journal: Br J Clin Pharmacol Date: 2018-04-10 Impact factor: 4.335
Authors: Christina Maria Gant; Isidor Minovic; Heleen Binnenmars; Laura de Vries; Ido Kema; André van Beek; Gerjan Navis; Stephan Bakker; Gozewijn Dirk Laverman Journal: J Endocr Soc Date: 2018-05-22
Authors: Anna J Anderson; Ruth Andrew; Natalie Z M Homer; Katherine A Hughes; Luke D Boyle; Mark Nixon; Fredrik Karpe; Roland H Stimson; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2021-03-08 Impact factor: 5.958